Carlumab is a high-affinity human monoclonal antibody that targets CCL2, blocking its interaction with the CCR2 receptor, thereby inhibiting CCL2-mediated tumour growth and suppressing the recruitment of monocytes/macrophages in the tumour microenvironment. It can be used for prostate and breast cancer research.
Purity:
95.00%
CAS Number:
[915404-94-3]
Target:
CCR
* VAT and and shipping costs not included. Errors and price changes excepted